Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound wave scanner could help ER doctors spot heart trouble in minutes

NCT ID NCT07653204

Diagnosis Sponsor: Austral Diagnostics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a non-invasive device called ADx-One that uses airborne ultrasound to capture chest vibrations. Researchers aim to develop a computer algorithm that can tell if a patient's chest pain or shortness of breath is due to a heart problem or something else. The study will enroll 2,500 adults in French emergency departments, but the device will not change their usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADx-One medical device (airborne ultrasound)
What this could lead to
If successful, this device could help emergency doctors quickly and accurately identify whether chest pain or shortness of breath is caused by a heart problem, speeding up treatment.
What could go wrong
This is an early-stage study to develop an algorithm, not a final test. The device is not yet proven to work, and it will not change patient care during the trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting to the emergency department for one or more of the following symptoms of less than 14 days' duration: acute non-traumatic dyspnea, or recent worsening of chronic dyspnea, or non-traumatic chest pain.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presentation to the emergency department for one or more of the following symptoms of less than 14 days' duration: acute non-traumatic dyspnea, or recent worsening of chronic dyspnea, or non-traumatic chest pain. * Patient able to sit on a chair or on the edge of the bed * Affiliation to national health insurance * Able to receive study information, understand the study, and provide written informed consent Exclusion Criteria: * • Immediate need for life-saving intervention or clinical instability incompatible with study procedures. * Shock or severe hemodynamic instability, for example systolic blood pressure \<90 mmHg for at least 30 minutes or associated signs of hypoperfusion. * Altered mental status or any condition preventing provision of valid informed consent. * Known cognitive impairment preventing informed consent. * Transfer to another care site before the ADx-One acquisition can be performed. * Known pregnancy * Minor, legally protected adult, or person deprived of liberty. * Participation in another interventional clinical study judged incompatible with this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chest pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chest Pain Dyspnea Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chest pain Dyspnea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • La Pitié-Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.